Literature DB >> 20010966

Parathyroid gland: cinacalcet-can it control hypercalcemia?

Angel L M de Francisco, Celestino Piñera.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20010966     DOI： 10.1038/nrendo.2009.245

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  10 in total

Review 1.  Calcium receptor and regulation of parathyroid hormone secretion.

Authors:  E M Brown
Journal:  Rev Endocr Metab Disord       Date:  2000-11       Impact factor: 6.514

2.  Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop.

Authors:  John P Bilezikian; Aliya A Khan; John T Potts
Journal:  J Clin Endocrinol Metab       Date:  2009-02       Impact factor: 5.958

3.  Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism.

Authors:  Munro Peacock; John P Bilezikian; Preston S Klassen; Matthew D Guo; Stewart A Turner; Dolores Shoback
Journal:  J Clin Endocrinol Metab       Date:  2004-11-02       Impact factor: 5.958

4.  Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study.

Authors:  Munro Peacock; Michael A Bolognese; Michael Borofsky; Simona Scumpia; Lulu Ren Sterling; Sunfa Cheng; Dolores Shoback
Journal:  J Clin Endocrinol Metab       Date:  2009-10-16       Impact factor: 5.958

Review 5.  New strategies for the treatment of hyperparathyroidism incorporating calcimimetics.

Authors:  Angel L M de Francisco
Journal:  Expert Opin Pharmacother       Date:  2008-04       Impact factor: 3.889

6.  KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).

Authors: 
Journal:  Kidney Int Suppl       Date:  2009-08       Impact factor: 10.545

7.  Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism.

Authors:  Claudio Marcocci; Philippe Chanson; Dolores Shoback; John Bilezikian; Laureano Fernandez-Cruz; Jacques Orgiazzi; Christoph Henzen; Sunfa Cheng; Lulu Ren Sterling; John Lu; Munro Peacock
Journal:  J Clin Endocrinol Metab       Date:  2009-05-26       Impact factor: 5.958

8.  Recurrence of hyperparathyroidism; a long-term follow-up after surgery for primary hyperparathyroidism.

Authors:  Gunilla Hedbäck; Anders Odén
Journal:  Eur J Endocrinol       Date:  2003-04       Impact factor: 6.664

9.  Quality of life and patient satisfaction after reoperation for primary hyperparathyroidism: analysis of long-term results.

Authors:  Christian Hasse; Helmut Sitter; Melanie Brune; Ina Wollenteit; Christoph Nies; Matthias Rothmund
Journal:  World J Surg       Date:  2002-06-13       Impact factor: 3.352

Review 10.  Medical management of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop.

Authors:  Aliya Khan; Andrew Grey; Dolores Shoback
Journal:  J Clin Endocrinol Metab       Date:  2009-02       Impact factor: 5.958
  10 in total
  1 in total

Review 1.  Cinacalcet as alternative treatment for primary hyperparathyroidism: achievements and prospects.

Authors:  Leonidas H Duntas; Nikolaos Stathatos
Journal:  Endocrine       Date:  2011-03-26       Impact factor: 3.633
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.